Home » Stocks » VERV

Verve Therapeutics, Inc. (VERV)

Stock Price: $49.92 USD -2.60 (-4.95%)
Updated Jul 27, 2021 4:00 PM EDT - Market closed
Market Cap 2.28B
Revenue (ttm) n/a
Net Income (ttm) -53.36M
Shares Out 45.75M
EPS (ttm) -1.17
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 27
Last Price $49.92
Previous Close $52.52
Change ($) -2.60
Change (%) -4.95%
Day's Open 52.44
Day's Range 49.05 - 53.49
Day's Volume 291,301
52-Week Range 29.50 - 73.80

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

The dictionary describes the word “verve” as having energy, or vitality. It seems appropriate, then, that shares of biotech startup Verve Therapeutics, Inc. ( VERV , Financial) are up nearly $170% to $5...

1 week ago - GuruFocus

Find out why these stocks are climbing higher.

Other stocks mentioned: NTLA, REGN
4 weeks ago - The Motley Fool

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Verve Therapeutics, a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the pr...

1 month ago - Business Wire

Verve Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.

1 month ago - SEC

A team of researchers from Verve Therapeutics and the Perelman School of Medicine at the University of Pennsylvania has developed a CRISPR gene-editing technique that lowered the levels of cholesterol i...

2 months ago - Phys.org

VerveTx Announces Nature Publication Highlighting its Use of Base Editing to Potently and Durably Lower Blood PCSK9 and LDL-C in Non-Human Primates

2 months ago - Business Wire

About VERV

Verve Therapeutics is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, or CVD, transforming treatment from chronic management to single-course gene editing medicines. The current paradigm of chronic care is fragile – requiring rigorous patient adherence, extensive healthcare infrastructure and regular healthcare access – and leaves many patients without adequate care. Our goal is to disrupt the chronic care model for CVD by providing a new therapeutic approach with single-course in vivo gene editi... [Read more...]

Industry
Biotechnology
IPO Date
Jun 17, 2021
CEO
Sekar Kathiresan, M.D.
Employees
63
Stock Exchange
NASDAQ
Ticker Symbol
VERV
Full Company Profile

Financial Performance

Financial Statements